Wolverine Trading
EIGR

Wolverine Trading’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Wolverine Trading’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-375
Closed -$76K – 7107
2021
Q3 		$76K Buy
+375
New +$89.2K ﹤0.01% 5901

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Trading's EIGR Position: Q4 2021 in Review

Wolverine Trading sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 375 shares — an estimated $76K sold.

Wolverine Trading first reported a position in EIGR in Q3 2021 and held it in 1 quarter. The position peaked at $76K in Q3 2021. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

  • Wolverine Trading reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Wolverine Trading sold 375 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $76K.
  • Wolverine Trading first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2021 and held it in 1 quarter.
  • Wolverine Trading's Eiger BioPharmaceuticals, Inc. position peaked at $76K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Wolverine Trading's 13F filing for Q4 2021, filed 14 Feb 2022.